Ohio – The American Association for Cancer Research (AACR) honored Dr. Carlo Croce, professor and chair
of the department of molecular virology, immunology and medical genetics and
director of Human Cancer Genetics at The Ohio State University Comprehensive
Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute (OSUCCC–James),with the seventh
annual Princess Takamatsu Memorial Lectureship at the recent AACR Annual
Meeting 2013 held in Washington, D.C.
who presented the lecture, “Causes and Consequences of microRNA Dysregulation
in Cancer,” was recognized for his research into the genetic mechanisms of
cancer. He discovered numerous oncogenes and established the role of microRNAs
in the development and progression of cancer.
Princess Takamatsu Memorial Lecture is presented to a scientist whose novel
and significant work had or may have a far-reaching impact on the detection,
diagnosis, treatment or prevention of cancer, and who embodies the dedication
of the princess to multinational collaborations. Her Imperial Highness Princess
Kikuko Takamatsu was instrumental in promoting cancer research and encouraging
cancer scientists. She became a champion for these causes following her
mother’s death from bowel cancer in 1933 at age 43.
am extremely honored to receive this prestigious award. I knew the princess and
attended several of the Takamatsu conferences,” said Croce, who served as chair
of the Princess Takamatsu Symposia in 1996. “I am truly delighted to have
received this honor during the AACR Annual Meeting.”
started his quest to find cancer-causing genes by analyzing cancer-specific
genomic abnormalities called chromosomal translocations. He began by studying
the translocation that characterizes Burkitt’s lymphoma and showing that it led
to the activation of the oncogene MYC. This finding was instrumental in
determining that the chromosomal translocations observed in many human leukemias
and lymphomas deregulate oncogenes, initiating the process of leukemia or
research led to the development of a microRNA gene expression chip to assess
global expression of microRNAs in tissues and tumors. He found that specific
microRNA signatures are associated with the diagnosis and prognosis of acute
myeloid leukemia, chronic lymphocytic leukemia (CLL), multiple myeloma, lung
cancer, colon cancer and other tumors and defined microRNAs that function as
oncogenes or tumor suppressors.
addition to being honored at the AACR Annual Meeting 2013 with the AACR
Princess Takamatsu Memorial Lectureship, Croce was inaugurated into the first
class of the Fellows of the AACR Academy. In 1990, he received the AACR-Richard
and Hinda Rosenthal Foundation Award, the AACR-Pezcoller International Award
for Cancer Research in 1999 and the AACR G.H.A. Clowes Memorial Award in 2006.
He also has served as a member of several AACR committees, as well as
editor-in-chief of Cancer Research (1990-2000), a member of the board of
directors (1990-1994) and chair of the 1998 AACR-Pezcoller International Award for
Cancer Research Committee.
has received numerous other accolades throughout his career, including two
Outstanding Investigator Awards from the National Cancer Institute, the Raymond
Bourgine Award and Gold Medal of Paris, an honorary doctorate in medicine from
Uppsala University in Sweden, the Rod and Ceil Mortel Lecture in Cancer
Research from Penn State University, the Italian Gold Medal for Public Health
and the Gottleib Award from The University of Texas MD Anderson Cancer Center.
He is also an elected member of the Institute of Medicine and the National
Academy of Sciences, an honorary member of the Japanese Cancer Society and a
foreign member of the Accademia Nazionale delle Scienze, delta dei XL in Italy.
in 1907, AACR is the world’s first and largest professional organization
dedicated to advancing cancer research and its mission to prevent and cure
cancer. AACR membership includes more than 34,000 laboratory, translational and
clinical researchers; population scientists; other health care professionals;
and cancer advocates residing in more than 90 countries. The AACR Annual
meeting attracts more than 17,000 attendees.
The Ohio State
University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute strives to create a cancer-free world by
integrating scientific research with excellence in education and
patient-centered care, a strategy that leads to better methods of prevention,
detection and treatment. Ohio State is one of only 41 National
(NCI)-designated Comprehensive Cancer Centers and one of only seven centers
funded by the NCI to conduct both phase I and phase II clinical trials. The NCI
recently rated Ohio State’s cancer program as “exceptional,” the highest rating
given by NCI survey teams. As the cancer program’s 228-bed adult patient-care
component, The James is a “Top Hospital” as named by the Leapfrog Group and one
of the top cancer hospitals in the nation as ranked by U.S. News & World
Eileen Scahill, Wexner Medical Center Public Affairs and Media
Relations, 614-293-3737, or Eileen.Scahill@osumc.edu